BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35662107)

  • 21. Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels.
    Horstmann M; Merseburger AS; von der Heyde E; Serth J; Wegener G; Mengel M; Feil G; Hennenlotter J; Nagele U; Anastasiadis A; Bokemeyer C; Stenzl A; Kuczyk M
    J Cancer Res Clin Oncol; 2005 Nov; 131(11):715-22. PubMed ID: 16080018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased expression of CD44 is associated with more aggressive behavior in clear cell renal cell carcinoma.
    Zanjani LS; Madjd Z; Abolhasani M; Rasti A; Fodstad O; Andersson Y; Asgari M
    Biomark Med; 2018 Jan; 12(1):45-61. PubMed ID: 29243496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Golgi Alpha-Mannosidase II as a Novel Biomarker Predicts Prognosis in Clear Cell Renal Cell Carcinoma.
    Li C; Guo L; Chen F; Yu W; Rao T; Ruan Y
    Oncol Res Treat; 2020; 43(6):264-275. PubMed ID: 32403105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma.
    Xu WH; Shi SN; Xu Y; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
    J Transl Med; 2019 Nov; 17(1):363. PubMed ID: 31703694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma.
    Zhou J; Deng Z; Chen Y; Gao Y; Wu D; Zhu G; Li L; Song W; Wang X; Wu K; He D
    Urol Oncol; 2015 Mar; 33(3):113.e9-17. PubMed ID: 25192834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma.
    Gremel G; Djureinovic D; Niinivirta M; Laird A; Ljungqvist O; Johannesson H; Bergman J; Edqvist PH; Navani S; Khan N; Patil T; Sivertsson Å; Uhlén M; Harrison DJ; Ullenhag GJ; Stewart GD; Pontén F
    BMC Cancer; 2017 Jan; 17(1):9. PubMed ID: 28052770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TMSB10 acts as a biomarker and promotes progression of clear cell renal cell carcinoma.
    Pan Q; Cheng G; Liu Y; Xu T; Zhang H; Li B
    Int J Oncol; 2020 May; 56(5):1101-1114. PubMed ID: 32319572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of clinicopathological parameters with FoxM1 expression in renal cell carcinoma.
    Kocarslan S; Guldur ME; Ekinci T; Ciftci H; Ozardali HI
    J Cancer Res Ther; 2014; 10(4):1076-81. PubMed ID: 25579557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Study on the Immunohistochemical Expressions of Leptin and Leptin Receptor in Clear Cell Renal Cell Carcinoma.
    Perumal K; Mun KS; Yap NY; Razack AHA; Gobe GC; Ong TA; Kuppusamy S; Rajandram R
    Biomed Res Int; 2020; 2020():3682086. PubMed ID: 32802842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Prognostic Significance of Protein Expression of CASZ1 in Clear Cell Renal Cell Carcinoma.
    Kim B; Jung M; Moon KC
    Dis Markers; 2019; 2019():1342161. PubMed ID: 31481981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteomic identification of Reticulocalbin 1 as potential tumor marker in renal cell carcinoma.
    Giribaldi G; Barbero G; Mandili G; Daniele L; Khadjavi A; Notarpietro A; Ulliers D; Prato M; Minero VG; Battaglia A; Allasia M; Bosio A; Sapino A; Gontero P; Frea B; Fontana D; Destefanis P
    J Proteomics; 2013 Oct; 91():385-92. PubMed ID: 23916412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumour necrosis factor receptor-associated factor-1 (TRAF-1) expression is increased in renal cell carcinoma patient serum but decreased in cancer tissue compared with normal: potential biomarker significance.
    Rajandram R; Yap NY; Pailoor J; Razack AH; Ng KL; Ong TA; Morais C; Gobe GC
    Pathology; 2014 Oct; 46(6):518-22. PubMed ID: 25158810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low NR3C2 levels correlate with aggressive features and poor prognosis in non-distant metastatic clear-cell renal cell carcinoma.
    Zhao Z; Zhang M; Duan X; Deng T; Qiu H; Zeng G
    J Cell Physiol; 2018 Oct; 233(10):6825-6838. PubMed ID: 29693713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma.
    Rasti A; Abolhasani M; Zanjani LS; Asgari M; Mehrazma M; Madjd Z
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):95-104. PubMed ID: 27638770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
    Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of CXCL13 as a potential biomarker in clear cell renal cell carcinoma via comprehensive bioinformatics analysis.
    Xu T; Ruan H; Song Z; Cao Q; Wang K; Bao L; Liu D; Tong J; Yang H; Chen K; Zhang X
    Biomed Pharmacother; 2019 Oct; 118():109264. PubMed ID: 31390578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.
    Argani P; Hicks J; De Marzo AM; Albadine R; Illei PB; Ladanyi M; Reuter VE; Netto GJ
    Am J Surg Pathol; 2010 Sep; 34(9):1295-303. PubMed ID: 20679884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma.
    Meyer HA; Tölle A; Jung M; Fritzsche FR; Haendler B; Kristiansen I; Gaspert A; Johannsen M; Jung K; Kristiansen G
    Eur Urol; 2009 Mar; 55(3):669-78. PubMed ID: 18450365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential expression and clinical relevance of MUC1 in renal cell carcinoma metastasis.
    Rausch S; Beermann J; Scharpf M; Hennenlotter J; Fend F; Stenzl A; Schollenberger D; Bedke J; Kruck S
    World J Urol; 2016 Dec; 34(12):1635-1641. PubMed ID: 26995391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GOLPH3 is a novel marker of poor prognosis and a potential therapeutic target in human renal cell carcinoma.
    Xue Y; Wu G; Liao Y; Xiao G; Ma X; Zou X; Zhang G; Xiao R; Wang X; Liu Q; Long D; Yang J; Xu H; Liu F; Liu M; Xie K; Huang R
    Br J Cancer; 2014 Apr; 110(9):2250-60. PubMed ID: 24595000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.